1. Tabalumab (Rheumatoid Arthritis) Forecast and Market
Analysis
Report Details:
Published:November 2012
No. of Pages: 45
Price: Single User License – US$6995
Tabalumab (Rheumatoid Arthritis) Forecast and Market Analysis
Summary
GlobalData has released its new PharmaPoint Drug Evaluation report, Tabalumab (Rheumatoid
Arthritis) Forecast and Market Analysis. The RA market is currently very dynamic, with the
November 6, 2012 FDA approval of Pfizer’s Xeljanz (tofacitinib) and novel oral therapies awaiting
approval such as: Eli Lilly’s anti-BAFF, tabalumab and JAK1,2 inhibitor, baricitinib, and Rigel/AZ’s
SYK inhibitor, fostamatinib. These compounds will challenge the current biologics in the attempt to
dislodge the stronghold of the TNF inhibitors, if their safety and efficacy profiles are proven once
they enter the market.
Eli Lilly and Company’s tabalumab is poised to become the first anti-BAFF mAb for the treatment
of RA. Tabalumab binds and inhibits the activity of soluble and cell surface-bound BAFF which
then decreases the activity, proliferation, and survival of B cells. It reduces levels of B cells
responsible for autoantibody production in RA without obliterating the body''s ability to generate
immunoglobulins. Tabalumab is currently in Phase III in the US and EU and in Phase I in Japan.
Scope
- Overview of RA, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment
guidelines as well as an overview on the competitive landscape.
- Detailed information on Tabalumab including product description, safety and efficacy profiles as
well as a SWOT analysis.
- Sales forecast for Tabalumab for the top eight countries from 2011 to 2022.
- Sales information covered for the US, France, Germany, the UK, Italy, Spain, Japan and
Australia.
Reasons to buy

2. - Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for
rheumatoid arthritis.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising
sales potential
- Make more informed business decisions from insightful and in-depth analysis of Tabalumab
performance
- Obtain sales forecast for Tabalumab from 2011 to 2022 in (the US, France, Germany, the UK,
Italy, Spain, Japan and Australia)
Get your copy of this report @
http://www.reportsnreports.com/reports/213176-tabalumab-rheumatoid-arthritis-forecast-and-market-
analysis.html
Major points covered in Table of Contents of this report include
1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 5
2 Introduction 6
2.1 Catalyst 6
2.2 Related Reports 7
3 Disease Overview 9
3.1 Etiology and Pathophysiology 9
3.1.1 Etiology 9
3.1.2 Pathophysiology 9
3.1.3 Prognosis 12
3.1.4 Quality of Life 12
3.2 Symptoms 13
4 Disease Management 14
4.1 Overview 14
4.2 Diagnosis 14
4.3 Treatment 17
5 Competitive Assessment 21
5.1 Overview 21
5.2 Strategic Competitor Assessment 21
6 Opportunity and Unmet Need 23
6.1 Overview 23
6.2 Unmet Needs 24
6.2.1 More rheumatologists in the field and physician knowledge of the disease 24
6.2.2 More cost-effective therapies through oral formulation and biosimilars 24
6.2.3 The development of predictive tests and discovery of biomarkers 24

3. 6.2.4 The discovery of curative therapies 25
6.2.5 Improved drug safety and efficacy profiles 25
6.3 Gap Analysis 26
6.4 Opportunities 27
6.4.1 Predictive tools for diagnosis and treatment 27
6.4.2 Target specificity 27
7 Pipeline Assessment 28
7.1 Overview 28
7.2 Promising Drugs in Clinical Development 29
8 Tabalumab (LY2127399) 31
8.1 Overview 31
8.2 Efficacy 32
8.3 Safety 32
8.4 Dosing and Formulation 32
8.5 Potential Clinical Positioning 33
8.6 Potential Commercial Positioning 33
8.7 Pricing and Reimbursement 33
8.8 SWOT Analysis 33
8.9 Forecast 34
9 Appendix 35
9.1 Abbreviations 35
9.2 Bibliography 37
9.3 Methodology 40
9.4 Forecasting Methodology 40
9.4.1 Diagnosed Rheumatoid Arthritis Patients 40
9.4.2 Percent Drug-treated Patients 40
9.4.3 General Pricing Assumptions 41
9.4.4 Pricing of Pipeline agents 42
9.5 Physicians and Specialists Included in this Study 42
9.6 Primary Research - Prescriber Survey 43
9.7 About the Authors 43
9.7.1 Analysts 43
9.7.2 Global Head of Healthcare 44
9.8 About GlobalData 45
9.9 Contact Us 45
9.10 Disclaimer 45
1.1 List of Tables
Table 1: Symptoms of Rheumatoid Arthritis 13
Table 2: Treatment Guidelines for Rheumatoid Arthritis 17
Table 3: Top Three Biologics Prescribed for Moderate-Severe Rheumatoid Arthritis by Market 20
Table 4: Treatment Guidelines for Rheumatoid Arthritis 22

4. Table 5: Overall Unmet Needs - Current Level of Attainment 23
Table 6: Clinical Unmet Needs - Gap Analysis, 2012 26
Table 7: Rheumatoid Arthritis - Phase Pipeline, 2012 29
Table 8: Comparison of Therapeutic Classes in Development for RA, 2012 30
Table 9: Product Profile - Tabalumab 31
Table 10: ACR Responses and DAS28 Scores for Tabalumab vs. Placebo at Week 16 32
Table 11: Tabalumab SWOT Analysis, 2012 33
Table 12: Global Sales Forecasts ($m) for Tabalumab 34
Table 13: Physicians Surveyed, By Country 43
1.2 List of Figures
Figure 1: Healthy and Arthritic Joint with Rheumatoid Arthritis 9
Figure 2: Rheumatoid Arthritis Biologic Drug Targets 11
Figure 3: Diagnosis Criteria for Rheumatoid Arthritis Based on 2010 ACR/EULAR Criteria Point
System 16
Figure 4: Severity of Rheumatoid Arthritis 16
Figure 5: Biologic Treatment Flow Based on Updated 2012 ACR Treatment Recommendations*
19
Figure 6: Competitive Assessment of Late-Stage Pipeline Agents in RA, 2012-2022 29
Contact: sales@reportsandreports.com for more information.